Jean-Paul and Martine Clozel represent the dream of just about every pharmaceutical researcher. After the multinational that employed them declined to pursue a compound they discovered, the Clozels founded a company to develop the drug. That startup birthed a blockbuster that has improved the lives of heart patients worldwide -- and the Clozels became billionaires in the process. For Johnson & Johnson, they’re a problem.
